Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Blinatumomab in Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
NCT07686042Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 4 trial of blinatumomab in Autoimmune Encephalitis (AE), Autoimmune cerebellitis (AC), sponsored by Beijing Tiantan Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
Autoimmune Encephalitis (AE)Autoimmune cerebellitis (AC)
Beyond the preview
Go deeper on NCT07686042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686042.